SecBot SecBot

QTTB

Q32 Bio Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001661998 Biotech & Drug Discovery
$8.29 −0.42 (−4.82%)
Nov 16 4:00 PM ET · prev $8.71
Market cap
$263.9M
Micro cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
$38.00
+358% · range $29.00–59.00
1 year
+262.0%
from $2.29 · Nov 17
30 days
+6.4%
from $7.79
52-week range
$1.93–21.38
−61% from high · low Nov 20
Avg volume 20D
360.2K
shares / day
Short interest
5.59M
≈18.7% of shares · −1.1%
Days to cover
12.1
at average volume
Insider net
+$29.6M
2 buyers · 3 sellers · 12 mo
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
22
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 0 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 8/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $30.0M at an average $8.00. 3 insiders sold $395.8K.

  • InstitutionsBULLISH

    Q3 2026: 22 added (3 new), 3 trimmed or exited. Largest new: Jpmorgan Chase & $10.1M.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.304 → −$0.283 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.1% to 5.59M shares. 12.1 days to cover, ≈18.7% of shares.

  • TrendRANGE

    9% below its 50-day average.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$10.1M
in new stakes · top 1 shown
FundMoveSharesValue
JPMORGAN CHASE & CONEW1,062,137$10.1M
VANGUARD CAPITAL MANAGEMENT LLCADD1,008,451$8.3M
AMERICAN CENTURY COMPANIES INCDOUBLED652,597$5.4M
MARSHALL WACE, LLPDOUBLED368,935$3.1M
BlackRock, Inc.DOUBLED340,353$2.8M
GEODE CAPITAL MANAGEMENT, LLCADD240,954$2.0M
Squarepoint Ops LLCDOUBLED192,095$1.6M
UBS Group AGDOUBLED164,470$1.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy8Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +358%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026Leerink Partners
INITIATE
INITIATEOutperform
Sep 28, 2026Jefferies
INITIATE
INITIATEBuy
Aug 24, 2026Morgan Stanley
INITIATE
INITIATEOverweight
Jul 28, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 13, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Jul 13, 2026Wells Fargo
UPGRADE
UPGRADEOverweight

Insider ledger

Form 4
$30.0M
bought · 2 insiders
$395.8K
sold · 3 insiders
+3.6%
vs their $8.00 cost
DateInsiderTypeValue
Oct 6, 2026
Kalowski Lee
CFO and President
Oct 6, 2026
SELL$10.8K
Oct 6, 2026
Morrison Jodie Pope
CEO
Oct 6, 2026
SELL$26.8K
Oct 6, 2026
Violette Shelia M.
Chief Scientific Officer
Oct 6, 2026
SELL$7.6K
Aug 25, 2026
Kalowski Lee
CFO and President
Aug 25, 2026
SELL$65.8K
Aug 25, 2026
Morrison Jodie Pope
CEO
Aug 25, 2026
SELL$163.0K
Aug 25, 2026
Violette Shelia M.
Chief Scientific Officer
Aug 25, 2026
SELL$46.3K
Jul 16, 2026
Kalowski Lee
CFO and President
Jul 16, 2026
AWARD53,250 sh
Jul 16, 2026
Morrison Jodie Pope
CEO
Jul 16, 2026
AWARD132,000 sh

Earnings setup

Estimates
−$0.28
EPS estimate, this quarter
+7%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.28-$0.35–-$0.21+6.2%$333.3K
Next Q-$0.41-$0.43–-$0.40-3.7%$0.00
Current FY-$1.40-$1.46–-$1.36+8.0%$333.3K
Next FY-$2.16-$3.15–-$1.22-1.1%$833.3K

Short side

FINRA· Oct 30, 2026
5,590,228
shares short
-1.1%
vs prior settlement
12.1
days to cover
≈18.7%
of shares outstanding
Trading halts
Sep 30, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Other
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
WALTHAM, Mass., Nov. 11, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-st
Oct 6, 2026 Insider
Kalowski Lee sold 1,301 shares
CFO and President @ $8.32 ($10.8K)
Oct 6, 2026 Insider
Morrison Jodie Pope sold 3,221 shares
CEO @ $8.32 ($26.8K)
Oct 6, 2026 Insider
Violette Shelia M. sold 917 shares
Chief Scientific Officer @ $8.32 ($7.6K)
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · NEW
1,062,137 shares ($10.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

22 filings · 1 press release · 5 bullish · 3 bearish · 14 neutral
All QTTB filing & press-release reports (23)